Try
VERTEX PHARMACEUTICALS INC / MA
VRTXUnited States
66 filed reports · 655 financial concepts · 41 earnings calls · 6 media appearances
Filed reports
66 reports · Jun 2016 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 98 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 31 | 5,275 | Jun 2016 to Jun 2026 |
| Current · 8-KSEC EDGAR | 25 | 98 | Jun 2020 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 10 | 6,448 | Dec 2016 to Dec 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 4, 2026 | 407 | Open |
| FY2026 Q2 | 8-K | Jun 30, 2026 | Aug 3, 2026 | 4 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 5, 2026 | 253 | Open |
| FY2026 Q1 | 8-K | Mar 31, 2026 | May 4, 2026 | 4 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 13, 2026 | 1,129 | Open |
| FY2025 Q4 | 8-K | Dec 31, 2025 | Feb 12, 2026 | 4 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 4, 2025 | 275 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Nov 3, 2025 | 4 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 5, 2025 | 178 | Open |
| FY2025 Q2 | 8-K | Jun 30, 2025 | Aug 4, 2025 | 4 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 6, 2025 | 177 | Open |
| FY2025 Q1 | 8-K | Mar 31, 2025 | May 5, 2025 | 4 | Open |
Financial data
655 concepts · 11,821 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial636 concepts · 10,976 facts · Dec 2008 to Jul 2026
- Amortized Cost68 · Jun 2018 to Jun 2026
- Fair Value68 · Jun 2018 to Jun 2026
- Cash and cash equivalents at carrying value58 · Dec 2014 to Jun 2026
- Costs and expenses58 · Dec 2014 to Jun 2026
- Income tax expense benefit58 · Dec 2014 to Jun 2026
- Net income loss58 · Dec 2014 to Jun 2026
- Operating income loss58 · Dec 2014 to Jun 2026
- Other nonoperating income expense58 · Dec 2014 to Jun 2026
- Revenue58 · Dec 2014 to Jun 2026
- Selling general and administrative expense58 · Dec 2014 to Jun 2026
- Accumulated other comprehensive income loss net of tax57 · Dec 2014 to Jun 2026
- Allocated share based compensation expense57 · Dec 2014 to Jun 2026
- Comprehensive income net of tax57 · Dec 2014 to Jun 2026
- Employee service share based compensation allocation of recognized period costs capitalized amount57 · Dec 2014 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value56 · Dec 2014 to Jun 2026
- Depreciation depletion and amortization56 · Dec 2014 to Jun 2026
- Increase decrease in accounts payable56 · Dec 2014 to Jun 2026
- Increase decrease in accounts receivable56 · Dec 2014 to Jun 2026
- Increase decrease in accrued liabilities and other operating liabilities56 · Dec 2014 to Jun 2026
- Increase decrease in inventories56 · Dec 2014 to Jun 2026
- Increase decrease in other deferred liability56 · Dec 2014 to Jun 2026
- Increase decrease in prepaid deferred expense and other assets56 · Dec 2014 to Jun 2026
- Net cash provided by used in operating activities56 · Dec 2014 to Jun 2026
- Other noncash income expense56 · Dec 2014 to Jun 2026
Product3 concepts · 380 facts · Dec 2014 to Jun 2026
- Revenue375 · Dec 2014 to Jun 2026
- Number of approved medicines3 · Dec 2024
- ALYFTREK2 · Dec 2025 to Mar 2026
Geography2 concepts · 198 facts · Dec 2014 to Jun 2026
- Revenue186 · Dec 2014 to Jun 2026
- Revenue (excluding assessed tax)12 · Mar 2024 to Sep 2024
Segment12 concepts · 169 facts · Dec 2022 to Jun 2026
- Cost of goods and services sold (US GAAP)28 · Dec 2022 to Jun 2026
- General and administrative expense (US GAAP)14 · Dec 2022 to Jun 2026
- Income tax expense benefit14 · Dec 2022 to Jun 2026
- Net income loss14 · Dec 2022 to Jun 2026
- Pharmaceuticals14 · Dec 2022 to Jun 2026
- Research and development asset acquired other than through business combination written off14 · Dec 2022 to Jun 2026
- Revenue14 · Dec 2022 to Jun 2026
- Segment reporting other item amount14 · Dec 2022 to Jun 2026
- Selling expense14 · Dec 2022 to Jun 2026
- Impairment of intangible assets indefinitelived excluding goodwill13 · Dec 2023 to Jun 2026
- Investment income interest and dividend12 · Dec 2022 to Dec 2025
- Investment income net4 · Mar 2025 to Jun 2026
Guidance2 concepts · 98 facts · Jul 2020 to Aug 2026
- Revenue Guidance50 · Jul 2020 to Aug 2026
- Effective Tax Rate Guidance48 · Jul 2020 to Aug 2026
Segments
747 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or servicesrt:ProductOrServiceAxis19 members · 344 facts
- Product88 · Dec 2016 to Jun 2026
- Collaborativeand Royalty44 · Dec 2016 to Jun 2026
- TRIKAFTAKAFTRIO39 · Dec 2017 to Jun 2026
- Kalydeco34 · Dec 2016 to Dec 2023
- ORKAMBI34 · Dec 2016 to Dec 2023
- SYMDEKOSYMKEVI32 · Dec 2016 to Dec 2023
- Manufactured Product Other18 · Dec 2022 to Jun 2026
- ALYFTREK15 · Dec 2023 to Jun 2026
- CASGEVY11 · Jun 2024 to Jun 2026
- JOURNAVX11 · Jun 2024 to Jun 2026
- Cystic Fibrosis Products4 · Mar 2025 to Jun 2026
- Incivek3 · Dec 2016 to Dec 2018
- CASGEVY And JOURNAVX2 · Mar 2024 to Mar 2025
- Collaborative Revenues2 · Sep 2017 to Sep 2018
- Manufactured Product Other Adjustments2 · Sep 2017 to Sep 2018
- Royalty Revenues2 · Sep 2017 to Sep 2018
- Cystic Fibrosis Medicine1 · Dec 2024
- Gene Therapy Medicine1 · Dec 2024
- Moderate To Severe Acute Pain Medicine1 · Dec 2024
Statement business segments1 member · 169 facts
- Pharmaceuticals169 · Dec 2022 to Jun 2026
Statement geographicalsrt:StatementGeographicalAxis5 members · 154 facts
- Europe42 · Dec 2016 to Jun 2026
- US42 · Dec 2016 to Jun 2026
- Other Countries Outsideofthe United Statesand Europe35 · Dec 2016 to Jun 2026
- Non Us26 · Sep 2017 to Jun 2026
- Outsidethe United States9 · Dec 2016 to Dec 2025
Statement geographicalus-gaap:StatementGeographicalAxis10 members · 44 facts
- Europe8 · Dec 2014 to Jun 2018
- US8 · Dec 2014 to Jun 2018
- Non Us4 · Mar 2017 to Jun 2018
- Other Countries Outsideofthe United Statesand Europe4 · Mar 2017 to Jun 2018
- Outsidethe United States4 · Dec 2014 to Dec 2017
- XX4 · Dec 2014 to Dec 2017
- Us3 · Mar 2024 to Sep 2024
- Europe3 · Mar 2024 to Sep 2024
- Non us3 · Mar 2024 to Sep 2024
- Other countries outsideofthe united statesand europe3 · Mar 2024 to Sep 2024
Product or serviceus-gaap:ProductOrServiceAxis9 members · 36 facts
- Kalydeco8 · Dec 2014 to Jun 2018
- ORKAMBI8 · Dec 2014 to Jun 2018
- Incivek4 · Dec 2014 to Dec 2017
- Product4 · Mar 2017 to Jun 2018
- SYMDEKOSYMKEVI4 · Mar 2017 to Jun 2018
- Collaborative Revenues2 · Jun 2017 to Jun 2018
- Manufactured Product Other2 · Mar 2017 to Mar 2018
- Manufactured Product Other Adjustments2 · Jun 2017 to Jun 2018
- Royalty Revenues2 · Jun 2017 to Jun 2018
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary136 claims from 8 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary207 claims from 8 reports · Sep 2024 to Jun 2026
- Risk-factor changes27 claims from 1 reports · Dec 2025
- Risk factors75 risks from 2 annual reports · 2024 to 2025
Earnings calls
41 calls · Jul 2016 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 3, 2026
- FY2026 Q1May 4, 2026
- FY2025 Q4Feb 12, 2026
- FY2025 Q3Nov 3, 2025
- FY2025 Q2Aug 4, 2025
- FY2025 Q1May 5, 2025
- FY2024 Q4Feb 10, 2025
- FY2024 Q3Nov 4, 2024
- FY2024 Q2Aug 1, 2024
- FY2024 Q1May 6, 2024
- FY2023 Q4Feb 5, 2024
- FY2023 Q3Nov 6, 2023
- FY2023 Q2Aug 1, 2023
- FY2023 Q1May 1, 2023
- FY2022 Q4Feb 7, 2023
- FY2022 Q3Oct 27, 2022
Executive media
6 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- Conference talks2 · Jul 2025
- Other appearances2 · Oct 2020 to Nov 2020
- TV interviews2 · Dec 2023 to Jan 2025
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.